TY - JOUR T1 - Rituximab in the Treatment of Refractory Anti-HMGCR Immune-mediated Necrotizing Myopathy JF - The Journal of Rheumatology JO - J Rheumatol SP - 623 LP - 627 DO - 10.3899/jrheum.171495 VL - 46 IS - 6 AU - Océane Landon-Cardinal AU - Yves Allenbach AU - Antoine Soulages AU - Aude Rigolet AU - Baptiste Hervier AU - Nicolas Champtiaux AU - Quentin Monzani AU - Guilhem Solé AU - Olivier Benveniste Y1 - 2019/06/01 UR - http://www.jrheum.org/content/46/6/623.abstract N2 - Objective. A pathogenic role of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibodies has been proposed. Our objective was to assess efficacy of rituximab (RTX) in anti-HMGCR immune-mediated necrotizing myopathy.Methods. All patients who had been treated with RTX were retrospectively reviewed to assess features and outcome.Results. Three of 9 patients demonstrated stable or improved muscle strength ± decline in creatine kinase levels, or T2/short-tau inversion recovery hypersignal decrease on magnetic resonance imaging following RTX treatment. RTX permitted intravenous immunoglobulin discontinuation and corticosteroid reduction to low dose in 2 patients.Conclusion. One-third of patients with refractory anti-HMGCR had improved strength or other evidence of improved disease activity following RTX treatment. ER -